If You Don’t Take a Position in this Marijuana Stock, You May Regret It

Here's a marijuana stock with rising large players volume that you may regret not taking a long position in. Then again, maybe not.

This company has developed the world's first prescription marijuana medicine that's now approved in many countries outside the United States.

This company's cannabis-formulated drug could generate peak annual sales of around $3 billion. At that rate, the stock could see its earnings jump a whopping 2,900% in the first year alone.

Beat Up Biotech Buying the Bottom For Turnaround In 2018

Many Biotech stocks are undervalued now thanks to the recent market pullback. Biotech investing will likely continue to be the best way to double your money in 2018.

With President Trump helping biotechnology companies get FDA approvals for new treatments faster, now seems to be a perfect time to take advantage of this sector’s coming growth surge.

This beat up biotech stock will likely turnaround and make investors who bought the bottom a lot of money by the end of 2018.

Antares Pharma PDUFA On Rising Large Players Volume

Antares Pharma has had a few set backs over the years and investors have waited patiently for the company to turn a profit.

Antares Pharma stock is seeing a strong run up in large players volume going into the February PDUFA for the Makena auto injector. Will 2018 finally be the year that this small-cap company turns a profit?

Is Ionis Pharmaceuticals Stock Ready To Explode Higher?

The chart of Ionis Pharmaceuticals doesn’t look like much but the fundamentals show eye-popping revenue growth.

Will 2018 be the year that Ionis Pharmaceuticals' stock explodes higher?

Synergy Pharmaceuticals Ahead of PDUFA

Synergy Pharmaceuticals has a PDUFA ruling coming within the next couple of days. The Twiggs Money Flow has started to run ahead of the FDA announcement.

Synergy Pharmaceuticals stock is starting to run higher ahead of its PDUFA date. Find out if you should be playing this stock for a quick pop.

Ablynx Stock Explodes Higher As Large Players Volume Rises

Ablynx stock is a late-stage clinical development company that is finally going to bring a product to market in Germany in 2018.

Summary

  • 2018 is the year that Ablynx brings Caplacizumab to market in Germany.
  • Novo Nordisk made an unsolicited bid for the company that was rejected.
  • Large players volume and the Twiggs Money Flow are surging higher.